- Home
- Our company
- Social impact
- Global health equity
- Global health equity news & press releases
Global health equity news & press releases
Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
Joint efforts aim to accelerate scale-up of WHO-recommended all-oral treatment regimens – a transition urgently needed to help protect the health of people with drug resistant-tuberculosis who are particularly vulnerable during COVID-19 pandemic In 2020, the initiative aims to reach at least 125,000 patients and could save National TB Programs in low- and middle-income countries up to USD$16 million
Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine
This marks the first major regulatory approval of a vaccine developed by Janssen The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen
The investigational Ebola vaccine regimen leverages Janssen’s established AdVac® and PER.C6® technologies and Bavarian Nordic’s MVA-BN® technology The AdVac® and PER.C6® technologies have been used to construct Janssen’s COVID-19, Zika, Respiratory Syncytial Virus (RSV) and HIV vaccine candidates
Global Advocacy and Communications Effort Launched to Drive Action Against COVID-19 and Stop Future Pandemics
South Africa’s Rugby World Cup Winning Captain Siya Kolisi kickstarts behavior change efforts “For Humankind”; calls on other stars from sports and screen to continue to rally around protective actions, like #MaskingForAFriend
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
A new global collaboration of philanthropic, non-profit and private sector organizations will work together to accelerate the development of novel TB treatment regimens for all TB patients. The global collaboration aims to create treatment regimens comprised of medicines to which there is limited or no drug resistance and that are ready for phase 3 development. The regimens could be an important step toward addressing the current global challenges around TB treatment complexity, and the diagnosis and treatment of drug-resistant TB.
Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in India
Program aims to raise awareness and reduce stigma of TB among young people in India, as part of Johnson & Johnson’s 10-year initiative to combat world’s leading infectious disease killer
Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak
Up to 200,000 Regimens of Janssen’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)
Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen
Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency
Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC)
The government of the DRC supports use of Janssen’s vaccine regimen as part of expanded public health response to country’s Ebola outbreak – the second-worst on record
